News
RAPS: FDA to Study Effect of Generic Drug Appearance on Patient Adherence
21.05.2015
Does the color, shape or size of a generic drug affect how willing patients are to adhere to existing treatment regimens? The US Food and Drug Administration (FDA) wants to know. FDA has long been
...
EMA: Draft guideline on clinical development of fixed combination medicinal products
21.05.2015
This guideline addresses the clinical development requirements of fixed combination medicinal products, which shall reflect their intended therapeutic use and indication. It replaces the guideline
...
GMP: FDA finalizes Guidelines for Biosimilars
21.05.2015
In February 2009, the US Food and Drug Administration has published three draft guidance documents on the development of biosimilars. Now, on 15 April, the FDA issued the finalized version of
...
GMP: India\'s Track&Trace System for the Export of Medicinal Products
21.05.2015
On 1 April the Indian Ministry of Commerce and Industry has supplemented a paragraph that substantiates the actual requirements and the timeline for the implementation of the Track and Trace
...
RAPS: FDA Legislation Tracker
14.05.2015
Each year, legislators introduce dozens of pieces of legislation hoping to change how the US Food and Drug Administration (FDA) regulates pharmaceuticals, medical devices, biologics and dietary
...
EMA: Risk minimisation strategy for high strength and fixed combination insulin products
14.05.2015
The guidance provides a strategy to minimise the potential risk of medication errors associated with the introduction of high strength insulins (i.e. higher than the EU-wide standard of 100
...
RAPS: EMA Says Companies Still Need to Report Side Effects of Donated Drugs
14.05.2015
Drug makers are frequently involved in relief and humanitarian aid efforts, often through donating their products. However, in light of recent outbreaks of neglected tropical diseases such as
...
EMA: Draft reflection paper on the chemical structure and properties criteria to be considered for the evaluation of new active substance (NAS) status of chemical substances
14.05.2015
This reflection paper is intended to reflect the current experience of the Quality Working Party (QWP), of the Committee for Medicinal Products for Human Use (CHMP) and the Co-ordination Group for
...
URPL: Information of President of The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products of May 04, 2015 concerning the avoidance of prescribing certain drugs including hepatitis C and amiodarone
14.05.2015
This document is announcement of President of The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products of May 04, 2015 concerning the avoidance of prescribing
...
URPL: The report on the activities of the European Medicines Agency (EMA) in 2014
14.05.2015
This document inludes information about the report on the activities of the European Medicines Agency (EMA) in 2014. ...